BMY Bristol Myers Squibb Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
22:20
Sep 09
Sep 09
r/biotech
BMS lags in cell therapy on BCMA reliance
The author argues BMS is a weaker cell therapy position than JnJ and Kite/Gilead because BMS still relies on BCMA targets while the rest of the field is moving away from BCMA. The implied mechanism is that BMS's cell therapy pipeline could lose competitive relevance as rivals adopt newer targets, weighing on its oncology franchise. No specific catalyst or time horizon is given. Main risk is that BMS's BCMA programs could still succeed commercially despite the shift.
BMY
Bristol Myers Squibb
Avoid
—
—
20:14
Sep 09
Sep 09
r/biotech
BMS cell therapies effective, growth ahead
The author claims Bristol Myers Squibb's cell therapy medicines are very effective, which they argue matters and will create substantial growth and opportunity. The implied mechanism is that strong clinical efficacy supports adoption and revenue expansion in BMS's cell therapy franchise. No specific catalyst, timeline, or risk is provided by the author.
BMY
Bristol Myers Squibb
Long
1ST
—
—
About BMY Investor Commentary
Across the available history and selected sources, Buzzberg tracks BMY (Bristol Myers Squibb) across 23 sources: 12 bullish vs 0 bearish calls from 37 authors. Historical directional balance: 14% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 85 total trade ideas tracked. Latest voices: u/Loose-Reflection2965, u/mmoran92, Jim Cramer.